{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:20:50Z","timestamp":1773926450885,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"am","delay-in-days":179,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/s1470-2045(25)00399-7","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:42:09Z","timestamp":1759300929000},"page":"1382-1392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study"],"prefix":"10.1016","volume":"26","author":[{"given":"Mingzhao","family":"Xing","sequence":"first","affiliation":[]},{"given":"Shuhuang","family":"Lin","sequence":"additional","affiliation":[]},{"given":"Aarti","family":"Mathur","sequence":"additional","affiliation":[]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[]},{"given":"Bela","family":"Bendlova","sequence":"additional","affiliation":[]},{"given":"Vlasta","family":"Kuklikova","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Melo","sequence":"additional","affiliation":[]},{"given":"Tito Teles","family":"Jesus","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Soares","sequence":"additional","affiliation":[]},{"given":"Carla","family":"Colombo","sequence":"additional","affiliation":[]},{"given":"Laura","family":"Fugazzola","sequence":"additional","affiliation":[]},{"given":"Norisato","family":"Mitsutake","sequence":"additional","affiliation":[]},{"given":"Michiko","family":"Matsuse","sequence":"additional","affiliation":[]},{"given":"Ayaka","family":"Sako","sequence":"additional","affiliation":[]},{"given":"Ana Patricia","family":"Estrada-Florez","sequence":"additional","affiliation":[]},{"given":"Luis G","family":"Carvajal-Carmona","sequence":"additional","affiliation":[]},{"given":"Mabel E","family":"Boh\u00f3rquez","sequence":"additional","affiliation":[]},{"given":"Caterina","family":"Mian","sequence":"additional","affiliation":[]},{"given":"Federica","family":"Vianello","sequence":"additional","affiliation":[]},{"given":"Christine J","family":"O'Neill","sequence":"additional","affiliation":[]},{"given":"Roderick","family":"Clifton-Bligh","sequence":"additional","affiliation":[]},{"given":"Agnieszka","family":"Czarniecka","sequence":"additional","affiliation":[]},{"given":"Barbara","family":"Jarzab","sequence":"additional","affiliation":[]},{"given":"Chan Kwon","family":"Jung","sequence":"additional","affiliation":[]},{"given":"Bayu","family":"Brahma","sequence":"additional","affiliation":[]},{"given":"Paul W","family":"Ladenson","sequence":"additional","affiliation":[]},{"given":"Young Joo","family":"Park","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1470-2045(25)00399-7_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"10.1016\/S1470-2045(25)00399-7_bib2","series-title":"AJCC cancer staging manual","author":"Amin","year":"2017"},{"key":"10.1016\/S1470-2045(25)00399-7_bib3","series-title":"AJCC cancer staging manual","author":"Edge","year":"2010"},{"key":"10.1016\/S1470-2045(25)00399-7_bib4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.oraloncology.2018.11.003","article-title":"A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinoma","volume":"87","author":"Nam","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/S1470-2045(25)00399-7_bib5","unstructured":"American Joint Committee on Cancer. Manual for Staging of Cancer, 1st edn. Chicago, IL, 1977."},{"key":"10.1016\/S1470-2045(25)00399-7_bib6","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0140-6736(13)60109-9","article-title":"Progress in molecular-based management of differentiated thyroid cancer","volume":"381","author":"Xing","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/S1470-2045(25)00399-7_bib7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ecl.2018.11.007","article-title":"Genetic-guided risk assessment and management of thyroid cancer","volume":"48","author":"Xing","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/S1470-2045(25)00399-7_bib8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1677\/erc.1.0978","article-title":"BRAF mutation in thyroid cancer","volume":"12","author":"Xing","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/S1470-2045(25)00399-7_bib9","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1210\/er.2007-0007","article-title":"BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications","volume":"28","author":"Xing","year":"2007","journal-title":"Endocr Rev"},{"key":"10.1016\/S1470-2045(25)00399-7_bib10","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/jama.2013.3190","article-title":"Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer","volume":"309","author":"Xing","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/S1470-2045(25)00399-7_bib11","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1530\/ERC-15-0533","article-title":"TERT promoter mutations in thyroid cancer","volume":"23","author":"Liu","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/S1470-2045(25)00399-7_bib12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1530\/ERC-13-0210","article-title":"Highly prevalent TERT promoter mutations in aggressive thyroid cancers","volume":"20","author":"Liu","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/S1470-2045(25)00399-7_bib13","doi-asserted-by":"crossref","first-page":"e1130","DOI":"10.1210\/jc.2013-4048","article-title":"TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer","volume":"99","author":"Liu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S1470-2045(25)00399-7_bib14","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","article-title":"BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence","volume":"32","author":"Xing","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(25)00399-7_bib15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/cen.12999","article-title":"TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas","volume":"85","author":"Bullock","year":"2016","journal-title":"Clin Endocrinol (Oxford)"},{"key":"10.1016\/S1470-2045(25)00399-7_bib16","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/cncr.29934","article-title":"Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients","volume":"122","author":"Song","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(25)00399-7_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/srep41752","article-title":"TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors","volume":"7","author":"Matsuse","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/S1470-2045(25)00399-7_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/ijms19092647","article-title":"Coexistence of TERT promoter mutations and the BRAF V600E alteration and its impact on histopathological features of papillary thyroid carcinoma in a selected series of polish patients","volume":"19","author":"Rusinek","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/S1470-2045(25)00399-7_bib19","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1530\/EC-19-0376","article-title":"BRAF and TERT mutations in papillary thyroid cancer patients of Latino ancestry","volume":"8","author":"Estrada-Fl\u00f3rez","year":"2019","journal-title":"Endocr Connect"},{"key":"10.1016\/S1470-2045(25)00399-7_bib20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S2213-8587(21)00027-9","article-title":"Thyroid cancer incidence trends by histology in 25 countries: a population-based study","volume":"9","author":"Miranda-Filho","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S1470-2045(25)00399-7_bib21","doi-asserted-by":"crossref","first-page":"e754","DOI":"10.1210\/jc.2013-3734","article-title":"TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas","volume":"99","author":"Melo","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S1470-2045(25)00399-7_bib22","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.mce.2014.10.019","article-title":"Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization","volume":"399","author":"Muzza","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/S1470-2045(25)00399-7_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13000-016-0458-6","article-title":"Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation","volume":"11","author":"Bae","year":"2016","journal-title":"Diagn Pathol"},{"key":"10.1016\/S1470-2045(25)00399-7_bib24","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1530\/EC-19-0069","article-title":"Somatic genetic alterations in a large cohort of pediatric thyroid nodules","volume":"8","author":"Pekova","year":"2019","journal-title":"Endocr Connect"},{"key":"10.1016\/S1470-2045(25)00399-7_bib25","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.31557\/APJCP.2020.21.11.3267","article-title":"Clinical utility of BRAF, NRAS, and TERT promoter mutation in preoperative thyroid fine-needle aspiration biopsy: A diagnostic study from Dharmais Cancer Hospital","volume":"21","author":"Perdana","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/S1470-2045(25)00399-7_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-86611-6","article-title":"The role of the size in thyroid cancer risk stratification","volume":"11","author":"Vianello","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/S1470-2045(25)00399-7_bib27","author":"Heinze"},{"key":"10.1016\/S1470-2045(25)00399-7_bib28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/1467-9868.00125","article-title":"Smoothing parameter selection in nonparametric regression using an improved Akaike information criterion","volume":"60","author":"Hurvich","year":"1998","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"10.1016\/S1470-2045(25)00399-7_bib29","series-title":"Methods of meta-analysis: correcting error and bias in research findings","author":"Schmidt","year":"2015"},{"key":"10.1016\/S1470-2045(25)00399-7_bib30","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jclinepi.2015.04.014","article-title":"A simple formula for the calculation of sample size in pilot studies","volume":"68","author":"Viechtbauer","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/S1470-2045(25)00399-7_bib31","author":"Kassambara"},{"key":"10.1016\/S1470-2045(25)00399-7_bib32","author":"Therneau"},{"key":"10.1016\/S1470-2045(25)00399-7_bib34","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jamaoncol.2016.3288","article-title":"Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality","volume":"3","author":"Liu","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/S1470-2045(25)00399-7_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1530\/ERC-16-0402","article-title":"A six-genotype genetic prognostic model for papillary thyroid cancer","volume":"24","author":"Shen","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/S1470-2045(25)00399-7_bib36","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1210\/clinem\/dgae327","article-title":"Coexisting RET\/PTC and TERT promoter mutation predict poor prognosis but effective RET and MEK targets in thyroid cancer","volume":"109","author":"Zhang","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S1470-2045(25)00399-7_bib37","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc3431","article-title":"Molecular pathogenesis and mechanisms of thyroid cancer","volume":"13","author":"Xing","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/S1470-2045(25)00399-7_bib38","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41467-018-03033-1","article-title":"Regulation of mutant TERT by BRAF V600E\/MAP kinase pathway through FOS\/GABP in human cancer","volume":"9","author":"Liu","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/S1470-2045(25)00399-7_bib39","doi-asserted-by":"crossref","first-page":"15846","DOI":"10.1073\/pnas.2004707117","article-title":"TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles Heel","volume":"117","author":"Tan","year":"2020","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["The Lancet Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204525003997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204525003997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T23:44:06Z","timestamp":1759621446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204525003997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1470204525003997"],"URL":"https:\/\/doi.org\/10.1016\/s1470-2045(25)00399-7","relation":{},"ISSN":["1470-2045"],"issn-type":[{"value":"1470-2045","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(25)00399-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(25)00424-3","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}